BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?
- PMID: 31722744
- PMCID: PMC6852734
- DOI: 10.1186/s13072-019-0315-4
BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?
Abstract
BRM (BRAHMA) is a core, SWI2/SNF2-type ATPase subunit of SWI/SNF chromatin-remodelling complex (CRC) involved in various important regulatory processes including development. Mutations in SMARCA2, a BRM-encoding gene as well as overexpression or epigenetic silencing were found in various human diseases including cancer. Missense mutations in SMARCA2 gene were recently connected with occurrence of Nicolaides-Baraitser genetics syndrome. By contrast, SMARCA2 duplication rather than mutations is characteristic for Coffin-Siris syndrome. It is believed that BRM usually acts as a tumour suppressor or a tumour susceptibility gene. However, other studies provided evidence that BRM function may differ depending on the cancer type and the disease stage, where BRM may play a role in the disease progression. The existence of alternative splicing forms of SMARCA2 gene, leading to appearance of truncated functional, loss of function or gain-of-function forms of BRM protein suggest a far more complicated mode of BRM-containing SWI/SNF CRCs actions. Therefore, the summary of recent knowledge regarding BRM alteration in various types of cancer and highlighting of differences and commonalities between BRM and BRG1, another SWI2/SNF2 type ATPase, will lead to better understanding of SWI/SNF CRCs function in cancer development/progression. BRM has been recently proposed as an attractive target for various anticancer therapies including the use of small molecule inhibitors, synthetic lethality induction or proteolysis-targeting chimera (PROTAC). However, such attempts have some limitations and may lead to severe side effects given the homology of BRM ATPase domain to other ATPases, as well as due to the tissue-specific appearance of BRM- and BRG1-containing SWI/SNF CRC classes. Thus, a better insight into BRM-containing SWI/SNF CRCs function in human tissues and cancers is clearly required to provide a solid basis for establishment of new safe anticancer therapies.
Keywords: BRM; Cancer; Epigenetics; SMARCA2; SWI/SNF chromatin-remodelling complex (CRC); Small molecule inhibitors; Synthetic lethality.
Conflict of interest statement
The authors declare no competing of interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6852734/bin/13072_2019_315_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6852734/bin/13072_2019_315_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6852734/bin/13072_2019_315_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6852734/bin/13072_2019_315_Fig4_HTML.gif)
Similar articles
-
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.BMC Cancer. 2020 Jan 6;20(1):12. doi: 10.1186/s12885-019-6425-3. BMC Cancer. 2020. PMID: 31906887 Free PMC article.
-
Striking phenotypic overlap between Nicolaides-Baraitser and Coffin-Siris syndromes in monozygotic twins with ARID1B intragenic deletion.Eur J Med Genet. 2020 Mar;63(3):103739. doi: 10.1016/j.ejmg.2019.103739. Epub 2019 Aug 14. Eur J Med Genet. 2020. PMID: 31421289
-
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21. J Pathol. 2016. PMID: 26356327 Free PMC article.
-
Clinical correlations of mutations affecting six components of the SWI/SNF complex: detailed description of 21 patients and a review of the literature.Am J Med Genet A. 2013 Jun;161A(6):1221-37. doi: 10.1002/ajmg.a.35933. Epub 2013 May 1. Am J Med Genet A. 2013. PMID: 23637025 Review.
-
SWI/SNF complex in disorder: SWItching from malignancies to intellectual disability.Epigenetics. 2012 Nov;7(11):1219-24. doi: 10.4161/epi.22299. Epub 2012 Sep 25. Epigenetics. 2012. PMID: 23010866 Free PMC article. Review.
Cited by
-
Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor.J Pers Med. 2024 Feb 20;14(3):224. doi: 10.3390/jpm14030224. J Pers Med. 2024. PMID: 38540967 Free PMC article.
-
Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.Cancer Genomics Proteomics. 2024 Jan-Feb;21(1):88-101. doi: 10.21873/cgp.20432. Cancer Genomics Proteomics. 2024. PMID: 38151294 Free PMC article.
-
Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model.Int J Clin Oncol. 2023 Nov;28(11):1487-1500. doi: 10.1007/s10147-023-02403-0. Epub 2023 Aug 27. Int J Clin Oncol. 2023. PMID: 37634210
-
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.Biomolecules. 2023 Jun 13;13(6):984. doi: 10.3390/biom13060984. Biomolecules. 2023. PMID: 37371564 Free PMC article. Review.
-
BRG1 is involved in vascular calcification in chronic renal disease via autophagy of vascular smooth muscle cells.iScience. 2023 Mar 23;26(4):106485. doi: 10.1016/j.isci.2023.106485. eCollection 2023 Apr 21. iScience. 2023. PMID: 37020968 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous